Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions

Antiviral Research

Volumn 91, Issue 2, 2011, Pages 161-166

  Zehbe, Ingeborg ^a   Richard, Christina ^b   Lee, Kyle F ^a   Campbell, Michael ^a   Hampson, Lynne ^c   Hampson, Ian N ^c  

^a Thunder Bay Regional Research Institute   (Canada)

^b Regional Cancer Care   (Canada)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

HPV related lesion; Non surgical treatment; Protease inhibitor lopinavir; Zinc finger ejecting compound

Indexed keywords

4,4 DITHIODIMORPHOLINE; AZOFORMAMIDE; DIAMIDE; LOPINAVIR; MORPHOLINE DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLORIMETRY; HUMAN; HUMAN CELL; KERATINOCYTE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; VIRUS RESISTANCE; WART VIRUS;

ANTIVIRAL AGENTS; AZO COMPOUNDS; CELL LINE, TUMOR; DIAMIDE; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; KERATINOCYTES; LETHAL DOSE 50; MICROBIAL SENSITIVITY TESTS; MORPHOLINES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PYRIMIDINONES;

HUMAN PAPILLOMAVIRUS;

EID: 79959401916     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.05.016     Document Type: Article

References (23)

1. Wise-Draper T.M., Wells S.I. Papillomavirus E6 and E7 proteins and their cellular targets. Front. Biosci. 2008, 13:1003-1017.
2. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:129-1136.
3. Pim D., Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010, 118:471-493.
4. Aguilar-Lemarroy A., Gariglio P., Whitaker N.J., Eichhorst S.T., zur Hausen H., Krammer P.H., Rösl F. Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95 mediated apoptosis. Oncogene 2002, 21:165-175.
5. Stöppler H., Stöppler M.C., Johnson E., Simbulan-Rosenthal C.M., Smulson M.E., Lyer S., Rosenthal D.S., Schlegel R. The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis. Oncogene 1998, 17:1207-1214.
6. Jones D.L., Thompson D.A., Münger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 1997, 239:97-107.
7. Dalal S., Gao Q., Androphy E.J., Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol. 1996, 70:683-688.
8. Nakagawa S., Watanabe S., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology 1995, 212:535-542.
9. Beerheide W., Bernard H.U., Tan Y.J., Ganesan A., Rice W.G., Ting A.E. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. J. Natl. Cancer Inst. 1999, 91:1211-1220.
10. Beerheide W., Sim M.M., Tan Y.J., Bernard H.U., Ting A.E. Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides. Bioorg. Med. Chem. 2000, 8:2549-2560.
11. Liu Y., Liu Z., Androphy E., Chen J., Baleja J.D. Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus. Biochemistry 2004, 43:7421-7431.
12. Baleja J.D., Cherry J.J., Liu Z., Gau H., Nicklaus M.C., Voigt J.H., Chen J.J., Androphy E.J. Identification of Inhibitors to Papillomavirus Type 16 E6 Protein Based on Three-dimensional Structures of Interacting Proteins. Antivir. Res. 2006, 72:49-59.
13. Rice W.G., Turpin J.A., Huang M., Clanton D., Buckheit R.W., Covell D.G., Wallqvist A., McDonnell N.B., DeGuzman R.N., Summers M.F., Zalkow L., Bader J.P., Haugwitz R.D., Sausville E.A. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat. Med. 1997, 3:341-345.
14. Hampson L., Kitchener H.C., Hampson I.N. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir. Ther. 2006, 11:813-825.
15. Piccinini M., Rinaudo M.T., Chiapello N., Ricotti E., Baldovino S., Mostert M., Tovo P.A. The human 26S proteasome is a target of antiretroviral agents. Aids 2002, 16:693-700.
16. Landis-Piwowar K.R., Chen D., Cui Q.C., Minic V., Becker F.F., Banik B.K., Dou Q.P. Apoptotic-inducing activity of novel polycyclic aromatic compounds in human leukemic cells. Int. J. Mol. Med. 2006, 18:931-935.
17. Batman, G., Oliver, A., Zehbe, I., Richard, C., Hampson, L., Hampson, I.N., 2011. The HIV protease inhibitor lopinavir up-regulates expression of the antiviral protein ribonuclease L in HPV positive cervical carcinoma cells. Antiv. Ther. 16, in press. doi:10.3851/IMP1786.
18. Liu C.H., Goldberg A.L., Qiu X.B. New insights into the role of the ubiquitin-proteasome pathway in the regulation of apoptosis. Chang Gung Med. J. 2007, 30:469-479.
19. Orlowski R.Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 1999, 6:303-313.
20. Yu C., Minemoto Y., Zhang J., Liu L., Tang F., Bui T.N., Xian J., Lin A. JNK Suppresses Apoptosis via Phosphorylation of the Proapoptotic Bcl-2 Family Protein BAD. Mol. Cell 2004, 13:329-340.
21. Shibata D.K., Arnheim N., Martin W.J. Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction. J. Exp. Med. 1988, 167:30-225.
22. Friedl F., Kimura F.I., Osato T., Ito Y. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc. Soc. Exp. Biol. Med. 1970, 135:543-545.
23. Bernstein W.B., Dennis P.A. Repositioning HIV protease inhibitors as cancer therapeutics. Curr. Opin. HIV AIDS 2008, 3:666-675.